NEWS BULLETIN

Alarm MARCH 2024, CRANBURY, NJ. “Reducing Delays of Breast Cancer Care Using an Innovative Digital Health Platform”  has been accepted for publication in the American Journal of Accountable Care. The article discusses how XpediteMD dramatically reduced breast cancer treatment delays in major health system. The article is due for publication June 2024.

Alarm FEBRUARY 2024, TORRANCE, CA. XpediteMD was a finalist in the CancerX Moonshot Accelerator Contest.

Alarm JANUARY 2024, WASHINGTON, DC. CMS issues new rule requiring electronic prior authorization and faster prior authorization decisions for Medicare Advantage members and others. Read more here

Alarm JANUARY 2024 TORRANCE, CA. XpediteMD submitted invited manuscript for publication in the Journal Of Clinical Pathways, “Time To Treatment and the Golden Hour: How Clinical Pathways Can Help"

Alarm DECEMBER 2023, TORRANCE, CA. XpediteMD joins the CancerX Moonshot accelerator competition, a White House initiative public-private partnership to boost innovation in the fight against cancer.

Alarm NOVEMBER 2023 TORRANCE, CA. XpediteMD submitted manuscript to American Journal of Accountable Care summarizing the XpediteMD experience at Intermountain Healthcare Nevada showing a 77% reduction in breast cancer time to treatment and an 80% reduction in administrative overhead.

Alarm NOVEMBER 2023, LA VEGAS, NV. SilverSummit Healthplan (Centene Nevada) sends out a press release lauding how XpediteMD is helping its breast cancer patients obtain breast cancer care much faster.

Alarm OCTOBER 2023, BOSTON, MA. Dennis R. Holmes presented invited plenary lecture at Clinical Pathways Congress + Cancer Care Business Exchange, “Time to Treat: Why It Mattes and How Pathways Can Help.”

Alarm OCTOBER 2023, BOSTON, MA. XpediteMD covered in news story in Journal of Clinical Pathways about XpediteMD’s innovative solution to the time to treatment problem.

Alarm OCTOBER 2023, BOSTON, MA. XpediteMD exhibited at upcoming annual meeting of Clinical Pathways Congress + Cancer Care Business Exchange and presented demo of XpediteMD in Vendor Forum

Alarm SEPTEMBER 2023. TORRANCE, CA. XpediteMD launches its
upgraded, scalable, multi-tenet, interoperable platform

Alarm AUGUST 2023, NEW ORLEANS, LA. XpediteMD presented results of quality improvement initiative at the National Medical Associations’ 24th annual meeting: “Golden Hour” Redefined: The relationship between timely care and cancer survival.

Alarm APRIL 2023, CHICAGO, IL. XpediteMD Co-Founder and CEO,
Dennis R. Holmes, MD, FACS, selected as the 2023 Health Policy
Scholar for the American College of Surgeons and American Society of Breast Surgeons. The XpediteMD innovation was instrumental in Dr. Holmes’ selection as the 2023 Health Policy Scholar.

Alarm MARCH 2024.  EAST WINDSOR TOWNSHIP, NJ. “Time to Treat and the “Golden Hour”: Why They Matter and How Clinical Pathways Can Help” has been accepted for publication in the Journal of Clinical Pathways. The article discusses how XpediteMD’s proprietary clinical pathways eliminate life-threatening cancer treatment delays. The article is due for publication June 2024.

Alarm JANUARY 2024-BOSTON, MA. XpediteMD, Inc. has advanced to the second round of the CancerX Accelerator/Mass Challenge competition. CancerX is a public-private partnership announced by The White House as a national accelerator to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.

Alarm APRIL 2023, CHICAGO, IL.  The American Medical Association launches an advocacy initiative to fix prior authorization which “hurts patients, physicians, and employers.” See how prior authorization affects you. The XpediteMD SaaS platform fixes prior authorization-related delays for cancer patients by establishing point of care prior authorizations, a new industry standard.

Alarm JANUARY 2023. LAS VEGAS, NV. XpediteMD signs Technology-Enabled Service contract with major health plan for use of the breast cancer module.

Alarm DECEMBER 2022. LAS VEGAS, NV. XpediteMD signs Technology-Enabled Service contract with major national health plan for use of the breast cancer module.

Alarm DECEMBER 2022, SAN ANTONIO, TX. XpediteMD presented results of quality improvement initiative at the 46th annual meeting of the San Antonio Breast Cancer Symposium reduced time to treatment by greater than 50%.

Alarm JUNE 2022, LAS VEGAS, NV. XpediteMD completes first of its kind IRB-approved quality health initiative at Intermountain Health Care Nevada which achieved a 77% reduction in time to treatment in only 12 months among Medicare Advantage breast cancer patients.

Alarm JUNE 2022, CHICAGO, IL. The Commission on Cancer (CoC) National Cancer Database announces a new breast quality measure that establishes “time to therapeutic breast surgery <60 days” as a surveillance measure for 1,500+ CoC-accredited sites—exactly what the XpediteMD is designed to address.

Alarm MAY 2022, COLUMBIA, MD. The American Society of Breast Surgeons announces a new national quality measure for timeliness of care for breast cancer, recommending that all newly diagnosed breast cancer patients initiate treatment for breast cancer within 60 days of the date of diagnosis—a challenge easily met by the XpediteMD.

Alarm MARCH 2022, SACRAMENTO, CA. The California Department of Managed Health Care and Department of Health Care Services fines L.A. Care, the nation’s largest publicly operated health plan, $55 million dollars in Enforcement Action for “operational failures” that contributed to delay of cancer care that resulted in “harm to members”—exactly the problem that the XpediteMD SaaS platform is designed to prevent.

Alarm OCTOBER 2021, LAS VEGAS, NV. XpediteMD launches proof-of-concept, IRB-approved, quality health initiative at Intermountain Health Care Nevada to evaluate ability of XpediteMD SaaS solution to reduce time to treatment for breast cancer patients with Medicare Advantage.